검색
검색 팝업 닫기

Ex) Article Title, Author, Keywords

Articles

Split Viewer

Review Article

Ann Liver Transplant 2021; 1(2): 113-122

Published online November 30, 2021 https://doi.org/10.52604/alt.21.0018

Copyright © The Korean Liver Transplantation Society.

Liver transplantation in Wilson’s disease: A systematic review

Emre Turgut , Cemalettin Aydin , Cuneyt Kayaalp , Sezai Yilmaz

Department of Gastrointestinal Surgery, University of Inonu Faculty of Medicine, Malatya, Turkey

Correspondence to:Emre Turgut
Department of Gastrointestinal Surgery, University of Inonu Faculty of Medicine, Malatya 44210, Turkey
E-mail: dr.emrtrgt@gmail.com
https://orcid.org/0000-0001-8196-1871

Received: June 2, 2021; Revised: July 29, 2021; Accepted: August 1, 2021

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/bync/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Wilson’s disease (WD) is a rare genetic disorder affecting the metabolism of copper that may present with neurological symptoms. In cases leading to hepatic failure, liver transplantation (LT) may be necessary. The aim of this paper is to examine the literature on LT cases related to WD in terms of disease characteristics, the neurological conditions of patients and survival rates. The keywords “Wilson and transplant*” were used to perform a title and abstract search across three databases (PubMed, Scopus, Web of Science) up until November 2018. The results from a total of 791 patients, mentioned in 28 studies, were analyzed. Thirty-nine point six percent of the patients received emergency LT and acute liver failure was more predominant in woman patients (61.7%-38.3%; p<0.0001). Live donations accounted for 36.6% of the transplants with none of these patients experiencing recurrence of disease. 36.4% of the patients displayed neurological symptoms prior to the transplant; however, following the operation these symptoms decreased by 74.2%. Survival rates for 1, 2, 3, 5, 10 years were 84%, 82%, 81%, 81%, and 80%, respectively. Further research into the reasons that acute liver failure in patients suffering from WD is more common among women is needed. Moreover, while mortality rates for up to one-year post-transplant are 16%, this rate is only 4% for the following 1–10 years. As neurological symptoms experienced prior to transplantation decrease by 74.2% after the operation, further studies should be carried out into the factors that determine potential neurological improvement.

Keywords: Liver, Transplantation, Review

Wilson’s disease (WD) is a genetic disorder affecting the metabolism of copper. The disease is caused by the mutations of homozygous or conjugated heterozygote (presence of two different mutant alleles) found in the ATP7B gene. This gene encodes the transmembrane copper carrier ATPase 2 which enables copper to enter the biliary tract for the synthesis of ceruloplasmin (the major copper-carrying protein in the blood) [1]. In a Wilson’s patient, the mutated ATP7B gene causes the copper to accumulate in the hepatocytes, as it cannot be released into the biliary tract. Excess copper detached from the ceruloplasmin also causes serious neuropsychiatric symptoms in secondary tissue such as the brain. The symptoms of this illness are varied and mostly develop between the 1st and 4th decades of life [2] with a prevalence of symptomatic disease of 1 in 30,000 people [3]. While most patients can be maintained with medical treatment, 5% develop acute liver failure (ALF) and 10% chronic liver failure (CLF) [4]. Liver transplantation (LT) can therefore be a lifesaving solution for such Wilson’s patients. The first case of liver transplant on a WD patient was published in 1971 [5] and since that time substantial progress in the usage of LT has been made. In the USA, 0.5%–1.5% of all LT performed are WD related [6,7]. In addition to hepatic insufficiency, LT is also important in terms of neurological complications. Post-transplant improvements have been recorded in patients with serious neurological symptoms [8]. However, LT-related complications and inconsistencies in post-transplant neurological improvement cast doubt on the validity of recommending neurological symptoms alone as indication for LT. In this study, all cases of LT in WD patients mentioned in the literature were analyzed in terms of demographic characteristics, indications for transplantation, pre-transplantation neurological status, transplantation results, neurological improvement and post-transplant survival rates.

Screening Strategy and Inclusion Criteria

A systematic review of all publications containing findings of LT related to WD was carried out. Using the keywords “Wilson and transplant*”, three databases (PubMed, Scopus, Web of Science) were scanned. Starting from the first recorded case, all publications until November 2018 were analyzed. Only English-language clinical trials were included in this study. Reviews, meta-analyses, case reports, poster presentations and non-human clinical studies were excluded from this review.

Data Extraction

Data extraction was completed by two authors, guided by a previously created database. The following data was recorded in the database: article name, first author name, country, center, year, type of study, number of patients, average age, patient group (pediatric or adult), gender, transplantation indication (CLF or ALF), presence of Kayser–Fleischer rings (KF), biochemical levels, neurological status pre-operative and post-operative, donor status (live, cadaver), post-transplant rejection and re-transplantation rates, causes of perioperative mortality and survival rates for 1, 2, 3, 5, and 10 years.

Statistical Method

Statistical analysis was conducted using MedCalc software (MedCalc Software, Ostend, Belgium). Both random-effect and fixed-effect models were to combine the studies and to determine the yearly mortality proportion %, and the 95% confidence interval. Statistical heterogeneity of included studies was tested using I2 statistics. Publication bias was tested by Egger’s weighted regression method and a p-value <0.05 was considered indicative of statistically significant publication bias.

During the initial screening 558 publications were found. After excluding recurring results, 399 publications remained. The selection process can be seen in Fig. 1. Twenty-eight clinical trials performed between 1993–2018 were also included in this study [7-34]. All the studies were retrospective and their parameters can be found in Table 1 and 2.

Table 1 . General features of the studies and patient characteristics

First authorYearCountryNo. of patientsChild/adultWoman/manMean age (yr)
Rela M1993UK12NA8/419
Schilsky M1994USA55NA32/2323.1
Bellary S1995USA3916/23NA23
Chen CL1997Taiwan70/74/321.4
Haberal M1999Turkey8NANA23.3
Eghtesad B1999USA4519/2626/1922.3
Schumacher G2001Germany21NA14/7NA
Emre S2001USA223/148/928
Wang X2005China2219/316/615.5
Tamura S2005Japan52/32/320
Medici V2005Italy370/3717/2027.5
Dhawan A2005UK5757/022/3511.9
Petrasek J2007Czech Republic350/3526/924.2
Marin C2007Spain14NANANA
Sevmis S2008Turkey24NA7/1715.6
Martin AP2008Germany110/116/529.7
PabÓn V2008France137/68/520
Markiewicz M2008Poland1313/012/115.5
Cheng F2009China3610/2620/16NA
Yoshitoshi EY2009Japan3224/817/1516.6
Peedikayil MC2013Saudi Arabia16NA7/919.3
Ohya Y2013Japan8NA4/415.7
Weiss KH2013Germany190/1913/629.4
Guillaud O2014France12146/7571/5022
Yagci MA2015Turkey9NA2/718.4
Lankarani KB2016Iran107NA43/6420.8
Choudhary NS2018India180/183/1532.4
Öcal R2018Turkey190/195/1426
Total825216/330393/36621.6
Percentage39.5/60.551.7/48.2

NA, not available.

The general characteristics of the 28 studies included in the review were summarized in the table.



Table 2 . General characteristics of the transplant patients

First authorNo. of transplantNeurological complicationKayser FleischerLiving or cadaveric donationAcute rejectChronic rejectRe-transplantFollow-up period (mon)Mortality
Rela M12NANANANANANANANA
Schilsky M55825NANANANA32.412
Bellary S39920NA3310NA8
Chen CL777NANANANA62.7NA
Haberal M8221/7NANANANA3
Eghtesad B451721NANANA11NA14
Schumacher G219NANANANANA62.4NA
Emre S17NA2NA20463.62
Wang X2291922/011218.51
Tamura S514NANANANA401
Medici V3710NANANANA464.610
Dhawan A10516NA402NA2
Petrasek J31NA6NANANANANA5
Marin C144NANANANANA962
Sevmis S2491821/3NANA121.75
Martin AP1154NANANA256.81
PabÓn V13262/1111NA1200
Markiewicz M1111NA2/920NA30.82
Cheng F361531NANANANA45.29
Yoshitoshi EY3242532/0NANA3886
Peedikayil MC16443/1341NA1231
Ohya Y6NANA2/4011NA1
Weiss KH194NANA102NA5
Guillaud O12129694/117517177215
Yagci MA9NANA7/2NANA236.60
Lankarani KB10760NANA3132133.515
Choudhary NS1837NA20NA152
Öcal R197NANANANANANANA
Total765/825280/739276/56696/16699/45517/45563/55362.2119/766
Percentage92.737.848.736.6/63.321.73.711.315.5

NA, not available.

The characteristics of patients who underwent liver transplantation in the studies were summarized in Table 2 .



Figure 1.Flowchart.

The average age of the 26 cases where age was mentioned was 21.4 (11–32) years. Two studies involved pediatric patients, 7 comprised adults and the remaining 19 focused on mixed groups of patients. In 18 detailed studies, a total of 216 (37.7%) pediatric and 356 (62.2%) adult patients were included. According to 25 studies that indicated gender, 393 (51.7%) patients were woman and 366 (48.2%) man. The average follow-up duration of the 20 studies that included this parameter, was 62.5 months. In total, 791 patients received a LT due to WD.

Results from 10 studies show that 96 (36.6%) patients received from live donors while 166 (63.4%) patients received cadaver donor transplants. In studies where transplant indications were given, 442 (60.3%) cases were due to CLF and 290 (39.6%) due to ALF. In 284 of 604 patients, (46.6%) KF rings were present. Average biochemical levels were: bilirubin: 15.2 (3–42.2) mg/dL; standardized prothrombin time (international normalized ratio): 3.04 (1.5–10); urine copper: 1,819.2 (256–4,119) µg; serum ceruloplasmin: 12.9 (7–22.2) mg/dL. Prior to their liver transplants, 247 out of 677 patients (36.4%) displayed neurological symptoms. There were 6 studies examining neurological status both before and after transplant [10-15]. When these studies were examined, a total of 101 patients had neurological complications before surgery. Neurological improvement was observed in 75 patients in the postoperative period. The studies highlighted a 74.2% post-transplant decrease in neurological symptoms over 101 patients. The details of these studies are summarized in Table 3. There were 19 studies that describe the perioperative and long-term causes of death. The most common cause was due to sepsis and the multiple organ dysfunction syndrome. These were followed by primary non-function and surgical complications. The details of the causes of mortality in these studies are shared in Table 4. It was observed that mortality in liver transplants performed for WD was mostly due to early-stage causes. Overall survival rates for 1, 2, 3, 5 and 10 years were 84%, 82%, 81%, 81%, and 80%, respectively (Fig. 2–6). In the 10-year survival analysis, 80% of the mortalities were observed in the first year, most probably within the perioperative period. No cases of recurrence were found in patients who had either cadaveric or live donor LT.

Table 3 . Neurological improvement in transplant patients

First authorNumber of patientsPriorAfter
Wang X229 (40.9)1 (4.5)
Chen CL77 (100)1 (14.2)
Marin C144 (28.5)1 (7.1)
Peedikayil MC164 (25)0 (0)
Lankarani KB10760 (56)20 (18.6)
Eghtesad B4517 (37.7)3 (6.6)
Total211101 (47.8)26 (12.3)

Values are presented as number only or number (%).

A 74.2% improvement in neurological complications was seen when looking at six studies examining neurological status before and after transplantation.



Table 4 . Causes of post-transplant mortality

Cause of deathNo. of patientsPercentage
Sepsis/MODS4442.7
Primer non-function98.7
Surgical complications87.7
Cardiac76.8
B-cell lymphoma54.8
Rejection43.8
Haemorrhage32.9
Brain abscess32.9
Other reasons2019.4

MODS, multi-organ dysfunction syndrome.

The most common causes of mortality after liver transplantation for Wilson’s disease are sepsis, MODS and other early complications.



Figure 2.One-year survival rate. CI, confidence interval.

WD clearly presents as an illness pertaining to children and young adults. The mean age of the overall patient group was 21.4 years. Studies show the mean age for LT to be 15 years (4–18) for children and 30 years for adults (19–68) [35-37]. In our study, 51.7% of the patients were woman and 48.2% man. Although the literature shows no significant difference between the genders in terms of WD diagnosis, studies indicate a significantly higher percentage of women with ALF due to WD [38,39]. In our study, we also saw that 61.7% of the patients who received LT due to ALF were woman compared to 38.2% man (p<0.0001). Further research is needed to determine the reasons why ALF is more common among women who suffer from WD.

Since the disease is caused by a defect in the body’s metabolism of copper, it causes symptoms related to excess copper accumulation in various tissues, especially the liver. Initially, certain patients may be diagnosed with symptoms of ALF or decompensated cirrhosis, while in other patients serious neurological symptoms may be more evident. The type of gene mutation may be important in identifying the presenting symptoms. While missense mutation in the gene is associated with older patients and prominent neurological symptoms, deletion mutation appears to be associated with younger patients and prominent hepatic symptoms [39,40]. However, this delineation is not absolute as most patients show a mix of both neurological and hepatic symptoms. Therefore, WD diagnosis should be made using a combination of laboratory tests and clinical findings. Twenty-four hour urine copper and liver copper concentrations, serum ceruloplasmin, ATP7B gene mutation, neurological symptoms, brain magnetic resonance imaging and hemolytic anemia are all important for the diagnosis of WD. KF rings are seen in only 50% of cases [41] and in our study, this rate was 46%. Diagnosis of WD in patients who suffer from ALF, where clinical findings and laboratory tests are less reliable and non-specific, is also more problematic. Most tests related to copper metabolism are not available in an emergency. In addition, serum ceruloplasmin levels were found to be unhelpful in the diagnosis of WD in 5 patients with idiopathic ALF [42,43]. In a study performed on 16 ALF patients to overcome this difficulty, a serum alkaline phosphatase to total serum bilirubin ratio of less than 2, along with a serum aspartate aminotransferase to serum alanine aminotransferase ratio of greater than 2.2 were found to be 100% sensitive and specific for WD-related ALF [44].

Significantly, LT immediately corrects the defect in copper metabolism. The normalization of serum ceruloplasmin levels post-transplantation usually occurs within the first month. As excess copper leaves the body relatively more slowly, it can take up to 6–9 months for urine copper levels to return to normal. In patients with a KF ring, the ring disappears completely in 60% of transplant patients, while a gradual fading is seen among other patients [45,46].

Another important post-transplant parameter is the improvement in neurological status. In this systematic review, the rate of neurological recovery after LT was also found to be high at 74.2%. However, whether or not neurological symptoms alone should be an indication for transplantation, still remains unclear. There are very few cases in the literature of a patient undergoing LT due to neurological symptoms while displaying normal liver functions [47,48]. In the study by Wang et al. [15], 88.9% neurological recovery was recorded. Eghtesad et al. [11] reported a 58.8% neurological improvement in their study, but advocated transplantation before symptoms became irreversible.

Factors affecting survival rates after LT related to WD, in the literature, are uncommon. No conclusive results were found in studies investigating the effect of factors such as age, sex, ALF or CLF. Medici et al. [8] reported the only factor affecting the survival rate to be neurological status and found that the survival rate of patients with severe neurological symptoms was significantly lower. Wang et al. [15] came to the same conclusion in their study. However, in this systematic review, long-term results were found to be very successful, independent of neurological involvement. According to this analysis, the most significant parameter affecting mortality rates is perioperative patient loss. In conclusion, although neurological status is not an indication for transplantation alone, it should be remembered that the reversal of symptoms in patients with persistent neurological involvement is far more problematic; therefore, such patients may have a lower quality of life post-LT, indirectly leading to an increase in mortality rates over the long term.

A further concern for WD is the potential transmission of the gene mutation in the case of LT from a live family donor, causing a recurrence of the disease. No such recurrence was found in our analysis of the live-donor transplant patient data. In fact, one study showed that none of the 11 children (9 ALF, 2 CLF) who underwent live-donor liver transplants from their parents had recurrence during the average follow-up period of 31 months [49]. It seems that since WD shows autosomal recessive inheritance, live donor liver transplants can be safely performed from individuals who carry heterozygous gene and have normal urine copper and serum ceruloplasmin levels.

Examination of the average survival rates for 1, 2, 3, 5, and 10 years reveal a success rate of 82%, 81%, 81%, and 80% respectively. Arnon et al. [6] in their study reported good survival rates for 1-year and 5-year terms as well as a better survival rate for WD related LT patients compared with transplant patients related to other illnesses. Higher survival rates can be attributed to the relatively young age for transplantation, fewer co-morbidities, and no disease recurrence. Similar results were obtained in our study.

This study has some limitations. First, most of the studies in the literature on liver transplants for WD are retrospective. The number of detailed prospective studies is few. Second, the number of studies providing sufficient detail in the preoperative and postoperative follow-up of neurological symptoms is not sufficient.

Liver transplants for WD have a higher survival rate than those for other indications. In addition, there is an improvement in neurological symptoms at a rate of 74.2% after transplantation. Mortality was mostly perioperative and was largely due to sepsis and multiple organ dysfunction syndrome. One-year, five-year and ten-year survival rates were similar. Perioperative mortality seems to be the most important parameter in determining long-term survival rates.

Conceptualization: ET, CA. Data curation: CK. Formal analysis: CA, CK. Investigation: ET, CA, CK. Methodology: ET, CK. Project administration: CK, SY. Resources: ET, CA, CK. Software: ET, CK. Supervision: SY. Validation: SY. Visualization: ET. Writing - original draft: ET. Writing - review & editing: CA, CK.

  1. Ferenci P. Regional distribution of mutations of the ATP7B gene in patients with Wilson disease: impact on genetic testing. Hum Genet 2006;120:151-159.
    Pubmed CrossRef
  2. Schoen RE, Sternlieb I. Clinical aspects of Wilson’s disease. Am J Gastroenterol 1990;85:1453-1457.
  3. Ala A, Schilsky ML. Wilson disease: pathophysiology, diagnosis, treatment, and screening. Clin Liver Dis 2004;8:787-805, viii.
    Pubmed CrossRef
  4. Schilsky ML. Liver transplantation for Wilson’s disease. Ann N Y Acad Sci 2014;1315:45-49.
    Pubmed CrossRef
  5. DuBois RS, Rodgerson DO, Martineau G, Shroter G, Giles G, Lilly J, et al. Orthotopic liver transplantation for Wilson’s disease. Lancet 1971;1:505-508.
    CrossRef
  6. Arnon R, Annunziato R, Schilsky M, Miloh T, Willis A, Sturdevant M, et al. Liver transplantation for children with Wilson disease: comparison of outcomes between children and adults. Clin Transplant 2011;25:E52-E60.
    Pubmed CrossRef
  7. Guillaud O, Dumortier J, Sobesky R, Debray D, Wolf P, Vanlemmens C, et al. Long term results of liver transplantation for Wilson’s disease: experience in France. J Hepatol 2014;60: 579-589.
    Pubmed CrossRef
  8. Medici V, Mirante VG, Fassati LR, Pompili M, Forti D, Del Gaudio M, et al.; Monotematica AISF 2000 OLT Study Group. Liver transplantation for Wilson’s disease: the burden of neurological and psychiatric disorders. Liver Transpl 2005;11: 1056-1063.
    Pubmed CrossRef
  9. Bellary S, Hassanein T, Van Thiel DH. Liver transplantation for Wilson’s disease. J Hepatol 1995;23:373-381.
    CrossRef
  10. Chen CL, Chen YS, Lui CC, Hsu SP. Neurological improvement of Wilson’s disease after liver transplantation. Transplant Proc 1997;29:497-498.
    CrossRef
  11. Eghtesad B, Nezakatgoo N, Geraci LC, Jabbour N, Irish WD, Marsh W, et al. Liver transplantation for Wilson’s disease: a single-center experience. Liver Transpl Surg 1999;5:467-474.
    Pubmed CrossRef
  12. Lankarani KB, Malek-Hosseini SA, Nikeghbalian S, Dehghani M, Pourhashemi M, Kazemi K, et al. Fourteen years of experience of liver transplantation for Wilson’s disease; a report on 107 cases from Shiraz, Iran. PLoS One 2016;11:e0167890.
    Pubmed KoreaMed CrossRef
  13. Marin C, Robles R, Parrilla G, Ramírez P, Bueno FS, Parrilla P. Liver transplantation in Wilson’s disease: are its indications established? Transplant Proc 2007;39:2300-2301.
    Pubmed CrossRef
  14. Peedikayil MC, Al Ashgar HI, Al Mousa A, Al Sebayel M, Al Kahtani K, Alkhail FA. Liver transplantation in Wilson’s disease: single center experience from Saudi Arabia. World J Hepatol 2013;5:127-132.
    Pubmed KoreaMed CrossRef
  15. Wang XH, Cheng F, Zhang F, Li XC, Kong LB, Li GQ, et al. Living-related liver transplantation for Wilson’s disease. Transpl Int 2005;18:651-656.
    Pubmed CrossRef
  16. Cheng F, Li GQ, Zhang F, Li XC, Sun BC, Kong LB, et al. Outcomes of living-related liver transplantation for Wilson’s disease: a single-center experience in China. Transplantation 2009;87:751-757.
    Pubmed CrossRef
  17. Choudhary NS, Saigal S, Saraf N, Rastogi A, Goja S, Bhangui P, et al. Outcome of living donor liver transplantation for Wilson’s disease in adults: a single center experience. J Clin Exp Hepatol 2018;8:132-135.
    Pubmed KoreaMed CrossRef
  18. Dhawan A, Taylor RM, Cheeseman P, De Silva P, Katsiyiannakis L, Mieli-Vergani G. Wilson’s disease in children: 37-year experience and revised King’s score for liver transplantation. Liver Transpl 2005;11:441-448.
    Pubmed CrossRef
  19. Emre S, Atillasoy EO, Ozdemir S, Schilsky M, Rathna Varma CV, Thung SN, et al. Orthotopic liver transplantation for Wilson’s disease: a single-center experience. Transplantation 2001;72:1232-1236.
    Pubmed CrossRef
  20. Haberal M, Moray G, Karakayali H, Arslan G, Boyacioglu S, Baysal C, et al. Liver transplantation for Wilson’s cirrhosis: one center’s experience. Transplant Proc 1999;31:3160-3161.
    CrossRef
  21. Markiewicz-Kijewska M, Szymczak M, Ismail H, Prokurat S, Teisseyre J, Socha P, et al. Liver transplantation for fulminant Wilson’s disease in children. Ann Transplant 2008;13:28-31.
  22. Martin AP, Bartels M, Redlich J, Hauss J, Fangmann J. A single-center experience with liver transplantation for Wilson’s disease. Clin Transplant 2008;22:216-221.
    Pubmed CrossRef
  23. Öcal R, Öcal S, Kırnap M, Moray G, Haberal M. Complications of liver transplant in adult patients with the hepatic form of Wilson disease. Exp Clin Transplant 2018;16 Suppl 1:38-40.
  24. Ohya Y, Okajima H, Honda M, Hayashida S, Suda H, Matsumoto S, et al. Re-evaluation of the indications for liver transplantation in Wilson’s disease based on the outcomes of patients referred to a transplant center. Pediatr Transplant 2013;17: 369-373.
    Pubmed CrossRef
  25. Pabón V, Dumortier J, Gincul R, Baulieux J, Ducerf C, Trépo C, et al. Long-term results of liver transplantation for Wilson’s disease. Gastroenterol Clin Biol 2008;32:378-381.
    Pubmed CrossRef
  26. Petrasek J, Jirsa M, Sperl J, Kozak L, Taimr P, Spicak J, et al. Revised King’s College score for liver transplantation in adult patients with Wilson’s disease. Liver Transpl 2007;13:55-61.
    Pubmed CrossRef
  27. Rela M, Heaton ND, Vougas V, McEntee G, Gane E, Farhat B, et al. Orthotopic liver transplantation for hepatic complications of Wilson’s disease. Br J Surg 1993;80:909-911.
    Pubmed CrossRef
  28. Schilsky ML, Scheinberg IH, Sternlieb I. Liver transplantation for Wilson’s disease: indications and outcome. Hepatology 1994;19:583-587.
    Pubmed CrossRef
  29. Schumacher G, Platz KP, Mueller AR, Neuhaus R, Luck W, Langrehr JM, et al. Liver transplantation in neurologic Wilson’s disease. Transplant Proc 2001;33:1518-1519.
    CrossRef
  30. Sevmis S, Karakayali H, Aliosmanoglu I, Yilmaz U, Ozcay F, Torgay A, et al. Liver transplantation for Wilson’s disease. Transplant Proc 2008;40:228-230.
    Pubmed CrossRef
  31. Tamura S, Sugawara Y, Kishi Y, Akamatsu N, Kaneko J, Makuuchi M. Living-related liver transplantation for Wilson’s disease. Clin Transplant 2005;19:483-486.
    Pubmed CrossRef
  32. Weiss KH, Schäfer M, Gotthardt DN, Angerer A, Mogler C, Schirmacher P, et al. Outcome and development of symptoms after orthotopic liver transplantation for Wilson disease. Clin Transplant 2013;27:914-922.
    Pubmed CrossRef
  33. Yagci MA, Tardu A, Karagul S, Ertugrul I, Ince V, Kirmizi S, et al. Influence of liver transplantation on neuropsychiatric manifestations of Wilson disease. Transplant Proc 2015;47:1469-1473.
    Pubmed CrossRef
  34. Yoshitoshi EY, Takada Y, Oike F, Sakamoto S, Ogawa K, Kanazawa H, et al. Long-term outcomes for 32 cases of Wilson’s disease after living-donor liver transplantation. Transplantation 2009;87:261-267.
    Pubmed CrossRef
  35. Ala A, Borjigin J, Rochwarger A, Schilsky M. Wilson disease in septuagenarian siblings: raising the bar for diagnosis. Hepatology 2005;41:668-670.
    Pubmed CrossRef
  36. Arnon R, Kerkar N, Davis MK, Anand R, Yin W, González-Peralta RP; SPLIT Research Group. Liver transplantation in children with metabolic diseases: the studies of pediatric liver transplantation experience. Pediatr Transplant 2010;14:796-805.
    Pubmed CrossRef
  37. Gitlin JD. Wilson disease. Gastroenterology 2003;125:1868-1877.
    Pubmed CrossRef
  38. Ala A, Walker AP, Ashkan K, Dooley JS, Schilsky ML. Wilson’s disease. Lancet 2007;369:397-408.
    CrossRef
  39. Walshe JM. Cause of death in Wilson disease. Mov Disord 2007;22:2216-2220.
    Pubmed CrossRef
  40. Scheinberg IH, Sternlieb I. Wilson disease and idiopathic copper toxicosis. Am J Clin Nutr 1996;63:842S-845S.
    Pubmed CrossRef
  41. Roberts EA, Schilsky ML; American Association for Study of Liver Diseases (AASLD). Diagnosis and treatment of Wilson disease: an update. Hepatology 2008;47:2089-2111.
    Pubmed CrossRef
  42. McCullough AJ, Fleming CR, Thistle JL, Baldus WP, Ludwig J, McCall JT, et al. Diagnosis of Wilson’s disease presenting as fulminant hepatic failure. Gastroenterology 1983;84:161-167.
    CrossRef
  43. Schilsky ML, Sternlieb I. Overcoming obstacles to the diagnosis of Wilson’s disease. Gastroenterology 1997;113:350-353.
  44. Korman JD, Volenberg I, Balko J, Webster J, Schiodt FV, Squires RH Jr, et al.; Pediatric and Adult Acute Liver Failure Study Groups. Screening for Wilson disease in acute liver failure: a comparison of currently available diagnostic tests. Hepatology 2008;48:1167-1174.
    Pubmed KoreaMed CrossRef
  45. Kasahara M, Takada Y, Egawa H, Fujimoto Y, Ogura Y, Ogawa K, et al. Auxiliary partial orthotopic living donor liver transplantation: Kyoto University experience. Am J Transplant 2005;5: 558-565.
    Pubmed CrossRef
  46. Schilsky ML. Diagnosis and treatment of Wilson’s disease. Pediatr Transplant 2002;6:15-19.
    Pubmed CrossRef
  47. Bax RT, Hässler A, Luck W, Hefter H, Krägeloh-Mann I, Neuhaus P, et al. Cerebral manifestation of Wilson’s disease successfully treated with liver transplantation. Neurology 1998; 51:863-865.
    Pubmed CrossRef
  48. Mason AL, Marsh W, Alpers DH. Intractable neurological Wilson’s disease treated with orthotopic liver transplantation. Dig Dis Sci 1993;38:1746-1750.
    Pubmed CrossRef
  49. Asonuma K, Inomata Y, Kasahara M, Uemoto S, Egawa H, Fujita S, et al. Living related liver transplantation from heterozygote genetic carriers to children with Wilson’s disease. Pediatr Transplant 1999;3:201-205.
    Pubmed CrossRef

Article

Review Article

Ann Liver Transplant 2021; 1(2): 113-122

Published online November 30, 2021 https://doi.org/10.52604/alt.21.0018

Copyright © The Korean Liver Transplantation Society.

Liver transplantation in Wilson’s disease: A systematic review

Emre Turgut , Cemalettin Aydin , Cuneyt Kayaalp , Sezai Yilmaz

Department of Gastrointestinal Surgery, University of Inonu Faculty of Medicine, Malatya, Turkey

Correspondence to:Emre Turgut
Department of Gastrointestinal Surgery, University of Inonu Faculty of Medicine, Malatya 44210, Turkey
E-mail: dr.emrtrgt@gmail.com
https://orcid.org/0000-0001-8196-1871

Received: June 2, 2021; Revised: July 29, 2021; Accepted: August 1, 2021

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/bync/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Wilson’s disease (WD) is a rare genetic disorder affecting the metabolism of copper that may present with neurological symptoms. In cases leading to hepatic failure, liver transplantation (LT) may be necessary. The aim of this paper is to examine the literature on LT cases related to WD in terms of disease characteristics, the neurological conditions of patients and survival rates. The keywords “Wilson and transplant*” were used to perform a title and abstract search across three databases (PubMed, Scopus, Web of Science) up until November 2018. The results from a total of 791 patients, mentioned in 28 studies, were analyzed. Thirty-nine point six percent of the patients received emergency LT and acute liver failure was more predominant in woman patients (61.7%-38.3%; p<0.0001). Live donations accounted for 36.6% of the transplants with none of these patients experiencing recurrence of disease. 36.4% of the patients displayed neurological symptoms prior to the transplant; however, following the operation these symptoms decreased by 74.2%. Survival rates for 1, 2, 3, 5, 10 years were 84%, 82%, 81%, 81%, and 80%, respectively. Further research into the reasons that acute liver failure in patients suffering from WD is more common among women is needed. Moreover, while mortality rates for up to one-year post-transplant are 16%, this rate is only 4% for the following 1–10 years. As neurological symptoms experienced prior to transplantation decrease by 74.2% after the operation, further studies should be carried out into the factors that determine potential neurological improvement.

Keywords: Liver, Transplantation, Review

INTRODUCTION

Wilson’s disease (WD) is a genetic disorder affecting the metabolism of copper. The disease is caused by the mutations of homozygous or conjugated heterozygote (presence of two different mutant alleles) found in the ATP7B gene. This gene encodes the transmembrane copper carrier ATPase 2 which enables copper to enter the biliary tract for the synthesis of ceruloplasmin (the major copper-carrying protein in the blood) [1]. In a Wilson’s patient, the mutated ATP7B gene causes the copper to accumulate in the hepatocytes, as it cannot be released into the biliary tract. Excess copper detached from the ceruloplasmin also causes serious neuropsychiatric symptoms in secondary tissue such as the brain. The symptoms of this illness are varied and mostly develop between the 1st and 4th decades of life [2] with a prevalence of symptomatic disease of 1 in 30,000 people [3]. While most patients can be maintained with medical treatment, 5% develop acute liver failure (ALF) and 10% chronic liver failure (CLF) [4]. Liver transplantation (LT) can therefore be a lifesaving solution for such Wilson’s patients. The first case of liver transplant on a WD patient was published in 1971 [5] and since that time substantial progress in the usage of LT has been made. In the USA, 0.5%–1.5% of all LT performed are WD related [6,7]. In addition to hepatic insufficiency, LT is also important in terms of neurological complications. Post-transplant improvements have been recorded in patients with serious neurological symptoms [8]. However, LT-related complications and inconsistencies in post-transplant neurological improvement cast doubt on the validity of recommending neurological symptoms alone as indication for LT. In this study, all cases of LT in WD patients mentioned in the literature were analyzed in terms of demographic characteristics, indications for transplantation, pre-transplantation neurological status, transplantation results, neurological improvement and post-transplant survival rates.

MATERIALS AND METHODS

Screening Strategy and Inclusion Criteria

A systematic review of all publications containing findings of LT related to WD was carried out. Using the keywords “Wilson and transplant*”, three databases (PubMed, Scopus, Web of Science) were scanned. Starting from the first recorded case, all publications until November 2018 were analyzed. Only English-language clinical trials were included in this study. Reviews, meta-analyses, case reports, poster presentations and non-human clinical studies were excluded from this review.

Data Extraction

Data extraction was completed by two authors, guided by a previously created database. The following data was recorded in the database: article name, first author name, country, center, year, type of study, number of patients, average age, patient group (pediatric or adult), gender, transplantation indication (CLF or ALF), presence of Kayser–Fleischer rings (KF), biochemical levels, neurological status pre-operative and post-operative, donor status (live, cadaver), post-transplant rejection and re-transplantation rates, causes of perioperative mortality and survival rates for 1, 2, 3, 5, and 10 years.

Statistical Method

Statistical analysis was conducted using MedCalc software (MedCalc Software, Ostend, Belgium). Both random-effect and fixed-effect models were to combine the studies and to determine the yearly mortality proportion %, and the 95% confidence interval. Statistical heterogeneity of included studies was tested using I2 statistics. Publication bias was tested by Egger’s weighted regression method and a p-value <0.05 was considered indicative of statistically significant publication bias.

RESULTS

During the initial screening 558 publications were found. After excluding recurring results, 399 publications remained. The selection process can be seen in Fig. 1. Twenty-eight clinical trials performed between 1993–2018 were also included in this study [7-34]. All the studies were retrospective and their parameters can be found in Table 1 and 2.

Table 1 .. General features of the studies and patient characteristics.

First authorYearCountryNo. of patientsChild/adultWoman/manMean age (yr)
Rela M1993UK12NA8/419
Schilsky M1994USA55NA32/2323.1
Bellary S1995USA3916/23NA23
Chen CL1997Taiwan70/74/321.4
Haberal M1999Turkey8NANA23.3
Eghtesad B1999USA4519/2626/1922.3
Schumacher G2001Germany21NA14/7NA
Emre S2001USA223/148/928
Wang X2005China2219/316/615.5
Tamura S2005Japan52/32/320
Medici V2005Italy370/3717/2027.5
Dhawan A2005UK5757/022/3511.9
Petrasek J2007Czech Republic350/3526/924.2
Marin C2007Spain14NANANA
Sevmis S2008Turkey24NA7/1715.6
Martin AP2008Germany110/116/529.7
PabÓn V2008France137/68/520
Markiewicz M2008Poland1313/012/115.5
Cheng F2009China3610/2620/16NA
Yoshitoshi EY2009Japan3224/817/1516.6
Peedikayil MC2013Saudi Arabia16NA7/919.3
Ohya Y2013Japan8NA4/415.7
Weiss KH2013Germany190/1913/629.4
Guillaud O2014France12146/7571/5022
Yagci MA2015Turkey9NA2/718.4
Lankarani KB2016Iran107NA43/6420.8
Choudhary NS2018India180/183/1532.4
Öcal R2018Turkey190/195/1426
Total825216/330393/36621.6
Percentage39.5/60.551.7/48.2

NA, not available..

The general characteristics of the 28 studies included in the review were summarized in the table..



Table 2 .. General characteristics of the transplant patients.

First authorNo. of transplantNeurological complicationKayser FleischerLiving or cadaveric donationAcute rejectChronic rejectRe-transplantFollow-up period (mon)Mortality
Rela M12NANANANANANANANA
Schilsky M55825NANANANA32.412
Bellary S39920NA3310NA8
Chen CL777NANANANA62.7NA
Haberal M8221/7NANANANA3
Eghtesad B451721NANANA11NA14
Schumacher G219NANANANANA62.4NA
Emre S17NA2NA20463.62
Wang X2291922/011218.51
Tamura S514NANANANA401
Medici V3710NANANANA464.610
Dhawan A10516NA402NA2
Petrasek J31NA6NANANANANA5
Marin C144NANANANANA962
Sevmis S2491821/3NANA121.75
Martin AP1154NANANA256.81
PabÓn V13262/1111NA1200
Markiewicz M1111NA2/920NA30.82
Cheng F361531NANANANA45.29
Yoshitoshi EY3242532/0NANA3886
Peedikayil MC16443/1341NA1231
Ohya Y6NANA2/4011NA1
Weiss KH194NANA102NA5
Guillaud O12129694/117517177215
Yagci MA9NANA7/2NANA236.60
Lankarani KB10760NANA3132133.515
Choudhary NS1837NA20NA152
Öcal R197NANANANANANANA
Total765/825280/739276/56696/16699/45517/45563/55362.2119/766
Percentage92.737.848.736.6/63.321.73.711.315.5

NA, not available..

The characteristics of patients who underwent liver transplantation in the studies were summarized in Table 2 ..



Figure 1. Flowchart.

The average age of the 26 cases where age was mentioned was 21.4 (11–32) years. Two studies involved pediatric patients, 7 comprised adults and the remaining 19 focused on mixed groups of patients. In 18 detailed studies, a total of 216 (37.7%) pediatric and 356 (62.2%) adult patients were included. According to 25 studies that indicated gender, 393 (51.7%) patients were woman and 366 (48.2%) man. The average follow-up duration of the 20 studies that included this parameter, was 62.5 months. In total, 791 patients received a LT due to WD.

Results from 10 studies show that 96 (36.6%) patients received from live donors while 166 (63.4%) patients received cadaver donor transplants. In studies where transplant indications were given, 442 (60.3%) cases were due to CLF and 290 (39.6%) due to ALF. In 284 of 604 patients, (46.6%) KF rings were present. Average biochemical levels were: bilirubin: 15.2 (3–42.2) mg/dL; standardized prothrombin time (international normalized ratio): 3.04 (1.5–10); urine copper: 1,819.2 (256–4,119) µg; serum ceruloplasmin: 12.9 (7–22.2) mg/dL. Prior to their liver transplants, 247 out of 677 patients (36.4%) displayed neurological symptoms. There were 6 studies examining neurological status both before and after transplant [10-15]. When these studies were examined, a total of 101 patients had neurological complications before surgery. Neurological improvement was observed in 75 patients in the postoperative period. The studies highlighted a 74.2% post-transplant decrease in neurological symptoms over 101 patients. The details of these studies are summarized in Table 3. There were 19 studies that describe the perioperative and long-term causes of death. The most common cause was due to sepsis and the multiple organ dysfunction syndrome. These were followed by primary non-function and surgical complications. The details of the causes of mortality in these studies are shared in Table 4. It was observed that mortality in liver transplants performed for WD was mostly due to early-stage causes. Overall survival rates for 1, 2, 3, 5 and 10 years were 84%, 82%, 81%, 81%, and 80%, respectively (Fig. 2–6). In the 10-year survival analysis, 80% of the mortalities were observed in the first year, most probably within the perioperative period. No cases of recurrence were found in patients who had either cadaveric or live donor LT.

Table 3 .. Neurological improvement in transplant patients.

First authorNumber of patientsPriorAfter
Wang X229 (40.9)1 (4.5)
Chen CL77 (100)1 (14.2)
Marin C144 (28.5)1 (7.1)
Peedikayil MC164 (25)0 (0)
Lankarani KB10760 (56)20 (18.6)
Eghtesad B4517 (37.7)3 (6.6)
Total211101 (47.8)26 (12.3)

Values are presented as number only or number (%)..

A 74.2% improvement in neurological complications was seen when looking at six studies examining neurological status before and after transplantation..



Table 4 .. Causes of post-transplant mortality.

Cause of deathNo. of patientsPercentage
Sepsis/MODS4442.7
Primer non-function98.7
Surgical complications87.7
Cardiac76.8
B-cell lymphoma54.8
Rejection43.8
Haemorrhage32.9
Brain abscess32.9
Other reasons2019.4

MODS, multi-organ dysfunction syndrome..

The most common causes of mortality after liver transplantation for Wilson’s disease are sepsis, MODS and other early complications..



Figure 2. One-year survival rate. CI, confidence interval.

DISCUSSION

WD clearly presents as an illness pertaining to children and young adults. The mean age of the overall patient group was 21.4 years. Studies show the mean age for LT to be 15 years (4–18) for children and 30 years for adults (19–68) [35-37]. In our study, 51.7% of the patients were woman and 48.2% man. Although the literature shows no significant difference between the genders in terms of WD diagnosis, studies indicate a significantly higher percentage of women with ALF due to WD [38,39]. In our study, we also saw that 61.7% of the patients who received LT due to ALF were woman compared to 38.2% man (p<0.0001). Further research is needed to determine the reasons why ALF is more common among women who suffer from WD.

Since the disease is caused by a defect in the body’s metabolism of copper, it causes symptoms related to excess copper accumulation in various tissues, especially the liver. Initially, certain patients may be diagnosed with symptoms of ALF or decompensated cirrhosis, while in other patients serious neurological symptoms may be more evident. The type of gene mutation may be important in identifying the presenting symptoms. While missense mutation in the gene is associated with older patients and prominent neurological symptoms, deletion mutation appears to be associated with younger patients and prominent hepatic symptoms [39,40]. However, this delineation is not absolute as most patients show a mix of both neurological and hepatic symptoms. Therefore, WD diagnosis should be made using a combination of laboratory tests and clinical findings. Twenty-four hour urine copper and liver copper concentrations, serum ceruloplasmin, ATP7B gene mutation, neurological symptoms, brain magnetic resonance imaging and hemolytic anemia are all important for the diagnosis of WD. KF rings are seen in only 50% of cases [41] and in our study, this rate was 46%. Diagnosis of WD in patients who suffer from ALF, where clinical findings and laboratory tests are less reliable and non-specific, is also more problematic. Most tests related to copper metabolism are not available in an emergency. In addition, serum ceruloplasmin levels were found to be unhelpful in the diagnosis of WD in 5 patients with idiopathic ALF [42,43]. In a study performed on 16 ALF patients to overcome this difficulty, a serum alkaline phosphatase to total serum bilirubin ratio of less than 2, along with a serum aspartate aminotransferase to serum alanine aminotransferase ratio of greater than 2.2 were found to be 100% sensitive and specific for WD-related ALF [44].

Significantly, LT immediately corrects the defect in copper metabolism. The normalization of serum ceruloplasmin levels post-transplantation usually occurs within the first month. As excess copper leaves the body relatively more slowly, it can take up to 6–9 months for urine copper levels to return to normal. In patients with a KF ring, the ring disappears completely in 60% of transplant patients, while a gradual fading is seen among other patients [45,46].

Another important post-transplant parameter is the improvement in neurological status. In this systematic review, the rate of neurological recovery after LT was also found to be high at 74.2%. However, whether or not neurological symptoms alone should be an indication for transplantation, still remains unclear. There are very few cases in the literature of a patient undergoing LT due to neurological symptoms while displaying normal liver functions [47,48]. In the study by Wang et al. [15], 88.9% neurological recovery was recorded. Eghtesad et al. [11] reported a 58.8% neurological improvement in their study, but advocated transplantation before symptoms became irreversible.

Factors affecting survival rates after LT related to WD, in the literature, are uncommon. No conclusive results were found in studies investigating the effect of factors such as age, sex, ALF or CLF. Medici et al. [8] reported the only factor affecting the survival rate to be neurological status and found that the survival rate of patients with severe neurological symptoms was significantly lower. Wang et al. [15] came to the same conclusion in their study. However, in this systematic review, long-term results were found to be very successful, independent of neurological involvement. According to this analysis, the most significant parameter affecting mortality rates is perioperative patient loss. In conclusion, although neurological status is not an indication for transplantation alone, it should be remembered that the reversal of symptoms in patients with persistent neurological involvement is far more problematic; therefore, such patients may have a lower quality of life post-LT, indirectly leading to an increase in mortality rates over the long term.

A further concern for WD is the potential transmission of the gene mutation in the case of LT from a live family donor, causing a recurrence of the disease. No such recurrence was found in our analysis of the live-donor transplant patient data. In fact, one study showed that none of the 11 children (9 ALF, 2 CLF) who underwent live-donor liver transplants from their parents had recurrence during the average follow-up period of 31 months [49]. It seems that since WD shows autosomal recessive inheritance, live donor liver transplants can be safely performed from individuals who carry heterozygous gene and have normal urine copper and serum ceruloplasmin levels.

Examination of the average survival rates for 1, 2, 3, 5, and 10 years reveal a success rate of 82%, 81%, 81%, and 80% respectively. Arnon et al. [6] in their study reported good survival rates for 1-year and 5-year terms as well as a better survival rate for WD related LT patients compared with transplant patients related to other illnesses. Higher survival rates can be attributed to the relatively young age for transplantation, fewer co-morbidities, and no disease recurrence. Similar results were obtained in our study.

This study has some limitations. First, most of the studies in the literature on liver transplants for WD are retrospective. The number of detailed prospective studies is few. Second, the number of studies providing sufficient detail in the preoperative and postoperative follow-up of neurological symptoms is not sufficient.

CONCLUSIONS

Liver transplants for WD have a higher survival rate than those for other indications. In addition, there is an improvement in neurological symptoms at a rate of 74.2% after transplantation. Mortality was mostly perioperative and was largely due to sepsis and multiple organ dysfunction syndrome. One-year, five-year and ten-year survival rates were similar. Perioperative mortality seems to be the most important parameter in determining long-term survival rates.

FUNDING

There was no funding related to this study.

CONFLICT OF INTEREST

All authors have no conflicts of interest to declare.

AUTHORS’ CONTRIBUTIONS

Conceptualization: ET, CA. Data curation: CK. Formal analysis: CA, CK. Investigation: ET, CA, CK. Methodology: ET, CK. Project administration: CK, SY. Resources: ET, CA, CK. Software: ET, CK. Supervision: SY. Validation: SY. Visualization: ET. Writing - original draft: ET. Writing - review & editing: CA, CK.

Fig 1.

Figure 1.Flowchart.
Annals of Liver Transplantation 2021; 1: 113-122https://doi.org/10.52604/alt.21.0018

Fig 2.

Figure 2.One-year survival rate. CI, confidence interval.
Annals of Liver Transplantation 2021; 1: 113-122https://doi.org/10.52604/alt.21.0018

Fig 3.

Figure 3.Two-year survival rate. CI, confidence interval.
Annals of Liver Transplantation 2021; 1: 113-122https://doi.org/10.52604/alt.21.0018

Fig 4.

Figure 4.Three-year survival rate. CI, confidence interval.
Annals of Liver Transplantation 2021; 1: 113-122https://doi.org/10.52604/alt.21.0018

Fig 5.

Figure 5.Five-year survival rate. CI, confidence interval.
Annals of Liver Transplantation 2021; 1: 113-122https://doi.org/10.52604/alt.21.0018

Fig 6.

Figure 6.Ten-year survival rate. CI, confidence interval.
Annals of Liver Transplantation 2021; 1: 113-122https://doi.org/10.52604/alt.21.0018

Table 1. General features of the studies and patient characteristics

First authorYearCountryNo. of patientsChild/adultWoman/manMean age (yr)
Rela M1993UK12NA8/419
Schilsky M1994USA55NA32/2323.1
Bellary S1995USA3916/23NA23
Chen CL1997Taiwan70/74/321.4
Haberal M1999Turkey8NANA23.3
Eghtesad B1999USA4519/2626/1922.3
Schumacher G2001Germany21NA14/7NA
Emre S2001USA223/148/928
Wang X2005China2219/316/615.5
Tamura S2005Japan52/32/320
Medici V2005Italy370/3717/2027.5
Dhawan A2005UK5757/022/3511.9
Petrasek J2007Czech Republic350/3526/924.2
Marin C2007Spain14NANANA
Sevmis S2008Turkey24NA7/1715.6
Martin AP2008Germany110/116/529.7
PabÓn V2008France137/68/520
Markiewicz M2008Poland1313/012/115.5
Cheng F2009China3610/2620/16NA
Yoshitoshi EY2009Japan3224/817/1516.6
Peedikayil MC2013Saudi Arabia16NA7/919.3
Ohya Y2013Japan8NA4/415.7
Weiss KH2013Germany190/1913/629.4
Guillaud O2014France12146/7571/5022
Yagci MA2015Turkey9NA2/718.4
Lankarani KB2016Iran107NA43/6420.8
Choudhary NS2018India180/183/1532.4
Öcal R2018Turkey190/195/1426
Total825216/330393/36621.6
Percentage39.5/60.551.7/48.2

NA, not available.

The general characteristics of the 28 studies included in the review were summarized in the table.


Table 2. General characteristics of the transplant patients

First authorNo. of transplantNeurological complicationKayser FleischerLiving or cadaveric donationAcute rejectChronic rejectRe-transplantFollow-up period (mon)Mortality
Rela M12NANANANANANANANA
Schilsky M55825NANANANA32.412
Bellary S39920NA3310NA8
Chen CL777NANANANA62.7NA
Haberal M8221/7NANANANA3
Eghtesad B451721NANANA11NA14
Schumacher G219NANANANANA62.4NA
Emre S17NA2NA20463.62
Wang X2291922/011218.51
Tamura S514NANANANA401
Medici V3710NANANANA464.610
Dhawan A10516NA402NA2
Petrasek J31NA6NANANANANA5
Marin C144NANANANANA962
Sevmis S2491821/3NANA121.75
Martin AP1154NANANA256.81
PabÓn V13262/1111NA1200
Markiewicz M1111NA2/920NA30.82
Cheng F361531NANANANA45.29
Yoshitoshi EY3242532/0NANA3886
Peedikayil MC16443/1341NA1231
Ohya Y6NANA2/4011NA1
Weiss KH194NANA102NA5
Guillaud O12129694/117517177215
Yagci MA9NANA7/2NANA236.60
Lankarani KB10760NANA3132133.515
Choudhary NS1837NA20NA152
Öcal R197NANANANANANANA
Total765/825280/739276/56696/16699/45517/45563/55362.2119/766
Percentage92.737.848.736.6/63.321.73.711.315.5

NA, not available.

The characteristics of patients who underwent liver transplantation in the studies were summarized in Table 2.


Table 3. Neurological improvement in transplant patients

First authorNumber of patientsPriorAfter
Wang X229 (40.9)1 (4.5)
Chen CL77 (100)1 (14.2)
Marin C144 (28.5)1 (7.1)
Peedikayil MC164 (25)0 (0)
Lankarani KB10760 (56)20 (18.6)
Eghtesad B4517 (37.7)3 (6.6)
Total211101 (47.8)26 (12.3)

Values are presented as number only or number (%).

A 74.2% improvement in neurological complications was seen when looking at six studies examining neurological status before and after transplantation.


Table 4. Causes of post-transplant mortality

Cause of deathNo. of patientsPercentage
Sepsis/MODS4442.7
Primer non-function98.7
Surgical complications87.7
Cardiac76.8
B-cell lymphoma54.8
Rejection43.8
Haemorrhage32.9
Brain abscess32.9
Other reasons2019.4

MODS, multi-organ dysfunction syndrome.

The most common causes of mortality after liver transplantation for Wilson’s disease are sepsis, MODS and other early complications.


References

  1. Ferenci P. Regional distribution of mutations of the ATP7B gene in patients with Wilson disease: impact on genetic testing. Hum Genet 2006;120:151-159.
    Pubmed CrossRef
  2. Schoen RE, Sternlieb I. Clinical aspects of Wilson’s disease. Am J Gastroenterol 1990;85:1453-1457.
  3. Ala A, Schilsky ML. Wilson disease: pathophysiology, diagnosis, treatment, and screening. Clin Liver Dis 2004;8:787-805, viii.
    Pubmed CrossRef
  4. Schilsky ML. Liver transplantation for Wilson’s disease. Ann N Y Acad Sci 2014;1315:45-49.
    Pubmed CrossRef
  5. DuBois RS, Rodgerson DO, Martineau G, Shroter G, Giles G, Lilly J, et al. Orthotopic liver transplantation for Wilson’s disease. Lancet 1971;1:505-508.
    CrossRef
  6. Arnon R, Annunziato R, Schilsky M, Miloh T, Willis A, Sturdevant M, et al. Liver transplantation for children with Wilson disease: comparison of outcomes between children and adults. Clin Transplant 2011;25:E52-E60.
    Pubmed CrossRef
  7. Guillaud O, Dumortier J, Sobesky R, Debray D, Wolf P, Vanlemmens C, et al. Long term results of liver transplantation for Wilson’s disease: experience in France. J Hepatol 2014;60: 579-589.
    Pubmed CrossRef
  8. Medici V, Mirante VG, Fassati LR, Pompili M, Forti D, Del Gaudio M, et al.; Monotematica AISF 2000 OLT Study Group. Liver transplantation for Wilson’s disease: the burden of neurological and psychiatric disorders. Liver Transpl 2005;11: 1056-1063.
    Pubmed CrossRef
  9. Bellary S, Hassanein T, Van Thiel DH. Liver transplantation for Wilson’s disease. J Hepatol 1995;23:373-381.
    CrossRef
  10. Chen CL, Chen YS, Lui CC, Hsu SP. Neurological improvement of Wilson’s disease after liver transplantation. Transplant Proc 1997;29:497-498.
    CrossRef
  11. Eghtesad B, Nezakatgoo N, Geraci LC, Jabbour N, Irish WD, Marsh W, et al. Liver transplantation for Wilson’s disease: a single-center experience. Liver Transpl Surg 1999;5:467-474.
    Pubmed CrossRef
  12. Lankarani KB, Malek-Hosseini SA, Nikeghbalian S, Dehghani M, Pourhashemi M, Kazemi K, et al. Fourteen years of experience of liver transplantation for Wilson’s disease; a report on 107 cases from Shiraz, Iran. PLoS One 2016;11:e0167890.
    Pubmed KoreaMed CrossRef
  13. Marin C, Robles R, Parrilla G, Ramírez P, Bueno FS, Parrilla P. Liver transplantation in Wilson’s disease: are its indications established? Transplant Proc 2007;39:2300-2301.
    Pubmed CrossRef
  14. Peedikayil MC, Al Ashgar HI, Al Mousa A, Al Sebayel M, Al Kahtani K, Alkhail FA. Liver transplantation in Wilson’s disease: single center experience from Saudi Arabia. World J Hepatol 2013;5:127-132.
    Pubmed KoreaMed CrossRef
  15. Wang XH, Cheng F, Zhang F, Li XC, Kong LB, Li GQ, et al. Living-related liver transplantation for Wilson’s disease. Transpl Int 2005;18:651-656.
    Pubmed CrossRef
  16. Cheng F, Li GQ, Zhang F, Li XC, Sun BC, Kong LB, et al. Outcomes of living-related liver transplantation for Wilson’s disease: a single-center experience in China. Transplantation 2009;87:751-757.
    Pubmed CrossRef
  17. Choudhary NS, Saigal S, Saraf N, Rastogi A, Goja S, Bhangui P, et al. Outcome of living donor liver transplantation for Wilson’s disease in adults: a single center experience. J Clin Exp Hepatol 2018;8:132-135.
    Pubmed KoreaMed CrossRef
  18. Dhawan A, Taylor RM, Cheeseman P, De Silva P, Katsiyiannakis L, Mieli-Vergani G. Wilson’s disease in children: 37-year experience and revised King’s score for liver transplantation. Liver Transpl 2005;11:441-448.
    Pubmed CrossRef
  19. Emre S, Atillasoy EO, Ozdemir S, Schilsky M, Rathna Varma CV, Thung SN, et al. Orthotopic liver transplantation for Wilson’s disease: a single-center experience. Transplantation 2001;72:1232-1236.
    Pubmed CrossRef
  20. Haberal M, Moray G, Karakayali H, Arslan G, Boyacioglu S, Baysal C, et al. Liver transplantation for Wilson’s cirrhosis: one center’s experience. Transplant Proc 1999;31:3160-3161.
    CrossRef
  21. Markiewicz-Kijewska M, Szymczak M, Ismail H, Prokurat S, Teisseyre J, Socha P, et al. Liver transplantation for fulminant Wilson’s disease in children. Ann Transplant 2008;13:28-31.
  22. Martin AP, Bartels M, Redlich J, Hauss J, Fangmann J. A single-center experience with liver transplantation for Wilson’s disease. Clin Transplant 2008;22:216-221.
    Pubmed CrossRef
  23. Öcal R, Öcal S, Kırnap M, Moray G, Haberal M. Complications of liver transplant in adult patients with the hepatic form of Wilson disease. Exp Clin Transplant 2018;16 Suppl 1:38-40.
  24. Ohya Y, Okajima H, Honda M, Hayashida S, Suda H, Matsumoto S, et al. Re-evaluation of the indications for liver transplantation in Wilson’s disease based on the outcomes of patients referred to a transplant center. Pediatr Transplant 2013;17: 369-373.
    Pubmed CrossRef
  25. Pabón V, Dumortier J, Gincul R, Baulieux J, Ducerf C, Trépo C, et al. Long-term results of liver transplantation for Wilson’s disease. Gastroenterol Clin Biol 2008;32:378-381.
    Pubmed CrossRef
  26. Petrasek J, Jirsa M, Sperl J, Kozak L, Taimr P, Spicak J, et al. Revised King’s College score for liver transplantation in adult patients with Wilson’s disease. Liver Transpl 2007;13:55-61.
    Pubmed CrossRef
  27. Rela M, Heaton ND, Vougas V, McEntee G, Gane E, Farhat B, et al. Orthotopic liver transplantation for hepatic complications of Wilson’s disease. Br J Surg 1993;80:909-911.
    Pubmed CrossRef
  28. Schilsky ML, Scheinberg IH, Sternlieb I. Liver transplantation for Wilson’s disease: indications and outcome. Hepatology 1994;19:583-587.
    Pubmed CrossRef
  29. Schumacher G, Platz KP, Mueller AR, Neuhaus R, Luck W, Langrehr JM, et al. Liver transplantation in neurologic Wilson’s disease. Transplant Proc 2001;33:1518-1519.
    CrossRef
  30. Sevmis S, Karakayali H, Aliosmanoglu I, Yilmaz U, Ozcay F, Torgay A, et al. Liver transplantation for Wilson’s disease. Transplant Proc 2008;40:228-230.
    Pubmed CrossRef
  31. Tamura S, Sugawara Y, Kishi Y, Akamatsu N, Kaneko J, Makuuchi M. Living-related liver transplantation for Wilson’s disease. Clin Transplant 2005;19:483-486.
    Pubmed CrossRef
  32. Weiss KH, Schäfer M, Gotthardt DN, Angerer A, Mogler C, Schirmacher P, et al. Outcome and development of symptoms after orthotopic liver transplantation for Wilson disease. Clin Transplant 2013;27:914-922.
    Pubmed CrossRef
  33. Yagci MA, Tardu A, Karagul S, Ertugrul I, Ince V, Kirmizi S, et al. Influence of liver transplantation on neuropsychiatric manifestations of Wilson disease. Transplant Proc 2015;47:1469-1473.
    Pubmed CrossRef
  34. Yoshitoshi EY, Takada Y, Oike F, Sakamoto S, Ogawa K, Kanazawa H, et al. Long-term outcomes for 32 cases of Wilson’s disease after living-donor liver transplantation. Transplantation 2009;87:261-267.
    Pubmed CrossRef
  35. Ala A, Borjigin J, Rochwarger A, Schilsky M. Wilson disease in septuagenarian siblings: raising the bar for diagnosis. Hepatology 2005;41:668-670.
    Pubmed CrossRef
  36. Arnon R, Kerkar N, Davis MK, Anand R, Yin W, González-Peralta RP; SPLIT Research Group. Liver transplantation in children with metabolic diseases: the studies of pediatric liver transplantation experience. Pediatr Transplant 2010;14:796-805.
    Pubmed CrossRef
  37. Gitlin JD. Wilson disease. Gastroenterology 2003;125:1868-1877.
    Pubmed CrossRef
  38. Ala A, Walker AP, Ashkan K, Dooley JS, Schilsky ML. Wilson’s disease. Lancet 2007;369:397-408.
    CrossRef
  39. Walshe JM. Cause of death in Wilson disease. Mov Disord 2007;22:2216-2220.
    Pubmed CrossRef
  40. Scheinberg IH, Sternlieb I. Wilson disease and idiopathic copper toxicosis. Am J Clin Nutr 1996;63:842S-845S.
    Pubmed CrossRef
  41. Roberts EA, Schilsky ML; American Association for Study of Liver Diseases (AASLD). Diagnosis and treatment of Wilson disease: an update. Hepatology 2008;47:2089-2111.
    Pubmed CrossRef
  42. McCullough AJ, Fleming CR, Thistle JL, Baldus WP, Ludwig J, McCall JT, et al. Diagnosis of Wilson’s disease presenting as fulminant hepatic failure. Gastroenterology 1983;84:161-167.
    CrossRef
  43. Schilsky ML, Sternlieb I. Overcoming obstacles to the diagnosis of Wilson’s disease. Gastroenterology 1997;113:350-353.
  44. Korman JD, Volenberg I, Balko J, Webster J, Schiodt FV, Squires RH Jr, et al.; Pediatric and Adult Acute Liver Failure Study Groups. Screening for Wilson disease in acute liver failure: a comparison of currently available diagnostic tests. Hepatology 2008;48:1167-1174.
    Pubmed KoreaMed CrossRef
  45. Kasahara M, Takada Y, Egawa H, Fujimoto Y, Ogura Y, Ogawa K, et al. Auxiliary partial orthotopic living donor liver transplantation: Kyoto University experience. Am J Transplant 2005;5: 558-565.
    Pubmed CrossRef
  46. Schilsky ML. Diagnosis and treatment of Wilson’s disease. Pediatr Transplant 2002;6:15-19.
    Pubmed CrossRef
  47. Bax RT, Hässler A, Luck W, Hefter H, Krägeloh-Mann I, Neuhaus P, et al. Cerebral manifestation of Wilson’s disease successfully treated with liver transplantation. Neurology 1998; 51:863-865.
    Pubmed CrossRef
  48. Mason AL, Marsh W, Alpers DH. Intractable neurological Wilson’s disease treated with orthotopic liver transplantation. Dig Dis Sci 1993;38:1746-1750.
    Pubmed CrossRef
  49. Asonuma K, Inomata Y, Kasahara M, Uemoto S, Egawa H, Fujita S, et al. Living related liver transplantation from heterozygote genetic carriers to children with Wilson’s disease. Pediatr Transplant 1999;3:201-205.
    Pubmed CrossRef
The Korean Liver Transplantation Society

Vol.3 No.2
November 2023

pISSN 2765-5121
eISSN 2765-6098

Stats or Metrics

Share this article on :

  • line